09/xxxxxx Page 1

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

NEWS WWW

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
                The CA Lexicon available in the CAPLUS and CA files
NEWS
        Dec 17
NEWS
         Feb 06 Engineering Information Encompass files have new names
                TOXLINE no longer being updated
NEWS
         Feb 16
                Search Derwent WPINDEX by chemical structure
NEWS
        Apr 23
                PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
         Apr 23
NEWS
        May 07
                DGENE Reload
NEWS
NEWS
         Jun 20
                 Published patent applications (A1) are now in USPATFULL
NEWS
      9
         JUL 13
                New SDI alert frequency now available in Derwent's
                 DWPI and DPCI
                 In-process records and more frequent updates now in
NEWS 10
        Aug 23
                 MEDLINE
                 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
        Aug 23
NEWS 11
                Adis Newsletters (ADISNEWS) now available on STN
NEWS 12
        Aug 23
                 IMSworld Pharmaceutical Company Directory name change
NEWS 13
        Sep 17
                 to PHARMASEARCH
                 Korean abstracts now included in Derwent World Patents
NEWS 14
        Oct 09
                 Index
NEWS 15
        Oct 09
                Number of Derwent World Patents Index updates increased
                Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 16
        Oct 15
NEWS 17
        Oct 22
                Over 1 million reactions added to CASREACT
NEWS 18
        Oct 22
                DGENE GETSIM has been improved
NEWS 19
        Oct 29
                AAASD no longer available
                New Search Capabilities USPATFULL and USPAT2
NEWS 20
        Nov 19
                TOXCENTER(SM) - new toxicology file now available on STN
NEWS 21
        Nov 19
NEWS 22
        Nov 29
                COPPERLIT now available on STN
                DWPI revisions to NTIS and US Provisional Numbers
NEWS 23
        Nov 29
                Files VETU and VETB to have open access
NEWS 24
        Nov 30
                WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 25
        Dec 10
                DGENE BLAST Homology Search
NEWS 26
        Dec 10
NEWS 27
        Dec 17
                WELDASEARCH now available on STN
                STANDARDS now available on STN
NEWS 28
        Dec 17
        Dec 17
                New fields for DPCI
NEWS 29
NEWS 30
        Dec 19
                CAS Roles modified
NEWS 31
        Dec 19
                1907-1946 data and page images added to CA and CAplus
NEWS EXPRESS
            August 15 CURRENT WINDOWS VERSION IS V6.0c,
              CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
              AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
             Welcome Banner and News Items
              Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
```

Enter NEWS followed by the item number or name to see news on that

CAS World Wide Web Site (general information)

specific topic.

All use of STN is subject to the provisions of the STN the tomer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:39:10 ON 28 DEC 2001

=> file medline, biosis, uspatful, dgene, japio, embase

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.15 0.15

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 18:39:35 ON 28 DEC 2001

FILE 'BIOSIS' ENTERED AT 18:39:35 ON 28 DEC 2001 COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 18:39:35 ON 28 DEC 2001 CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:39:35 ON 28 DEC 2001 COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 18:39:35 ON 28 DEC 2001 COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'EMBASE' ENTERED AT 18:39:35 ON 28 DEC 2001 COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

=> s codon replacment

L1 0 CODON REPLACMENT

=> s codon

L2 107597 CODON

=> s 12 and replacement

L3 7806 L2 AND REPLACEMENT

=> s 13 and encoding protein

L4 101 L3 AND ENCODING PROTEIN

=> s 14 and frequency

L5 40 L4 AND FREQUENCY

=> s 15 and less common

L6 0 L5 AND LESS COMMON

=> d 15 ti abs ibib 1-10

L5

ANSWER 1 OF 40 USETFULL Evolution of whom cells and organisms by recursive sequence TΙ

recombination

The invention provides methods employing iterative cycles of ΑB recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:220889 USPATFULL

Evolution of whole cells and organisms by recursive TITLE:

sequence recombination

delCardayre, Stephen, Los Gatos, CA, United States INVENTOR(S):

Tobin, Matthew, San Jose, CA, United States

Stemmer, William P. C., Los Gatos, CA, United States

Ness, Jon E., Sunnyvale, CA, United States Minshull, Jeremy, Menlo Park, CA, United States Patten, Phillip, Mountain View, CA, United States Subramanian, Venkiteswatan, Danville, CA, United

States

Castle, Linda, Mountain View, CA, United States

Bass, Steve, Hillsborough, CA, United States

PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S.

corporation)

NUMBER DATE KIND _____ PATENT INFORMATION: US 6326204 B1 20011204 US 1998-116188 19980715

(9) APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1998-US852, filed

on 16 Jan 1998

DOCUMENT TYPE: Utility GRANTED FILE SEGMENT:

PRIMARY EXAMINER: Whisenant, Ethan

LEGAL REPRESENTATIVE: Kruse, Norman J., Quine, Jonathan AlanLaw Offices of

Jonathan Alan Quine

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 35 Drawing Figure(s); 35 Drawing Page(s)

LINE COUNT: 5175

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 2 OF 40 USPATFULL L_5

Methods and compositions for polypeptide engineering ΤI

Methods are provided for the evolution of proteins of industrial and AB pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also

disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:208690 USPATFULL

TITLE: Methods and compositions for polypeptide engineering INVENTOR(S):

Patten, Phillip A., Mountain View, CA, United States Stemmer, Willem P. C., Los Gatos, CA, United States

Maxygen, Inc., Redwood City, CA, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE US 6319713 B1 20011120 US 1999-339904 19990625 (9) PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.: Division of Ser. No. US 1996-769062, filed on 18 Dec 996 Continuation-in-part of Ser_No. US 1994-198431,

led on 17 Feb 1994, now patent Pat. No. US

5605793

, said Ser. No. US 769062 And Ser. No. US 339904 Continuation-in-part of Ser. No. US 537874, now patented, Pat. No. US 5830721, said Ser. No. US

339904

And Ser. No. US 339904 And Ser. No. WO 1996-US5480, filed on 18 Dec 1996 Continuation-in-part of Ser. No. US 1996-722660, filed on 27 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-675502, filed on 3 Jul 1996, now patented, Pat. No. US 5928905 Continuation-in-part of Ser. No. US 1996-721824, filed on 20 May 1996 Continuation-in-part of Ser. No. US 1996-650400, filed on 20 May 1996, now patented, Pat. No. US 5837458 Continuation-in-part of Ser. No. US 1996-621430, filed on 25 Mar 1996, now abandoned Continuation-in-part of Ser. No. US 1996-621859, filed on 25 Mar 1996, now patented, Pat. No. US 6117679 Continuation-in-part of Ser. No. US 1995-425684, filed on 18 Apr 1995, now patented, Pat. No. US 5834252 Continuation-in-part of Ser. No. US 1995-425684, filed on 18 Apr 1995, now patented, Pat. No. US 5834252

DOCUMENT TYPE: FILE SEGMENT:

Utility GRANTED

PRIMARY EXAMINER:

Whisenant, Ethan

LEGAL REPRESENTATIVE:

Kruse, Norman J., Quire, Jonathan AlanThe Law Office

Jonathan Alan Quire

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

53 1

NUMBER OF DRAWINGS:

2 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 3 OF 40 USPATFULL

ΤI Methods and compositions for polypeptide engineering

Methods are provided for the evolution of proteins of industrial and AB pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also

disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2001:178848 USPATFULL

TITLE: INVENTOR(S): Methods and compositions for polypeptide engineering Patten, Phillip A., Mountain View, CA, United States Stemmer, Willem P.C., Los Gatos, CA, United States

PATENT ASSIGNEE(S):

Maxygen, Inc., Redwood City, CA, United States (U.S.

corporation)

NUMBER KIND DATE US 6303344 B1 20011016 US 1999-339913 19990624 PATENT INFORMATION: APPLICATION INFO.: 19990624 (9)

RELATED APPLN. INFO.:

Division of Ser. No. US 1996-769062, filed on 18 Dec

1996

DOCUMENT TYPE: FILE SEGMENT:

Utility GRANTED

PRIMARY EXAMINER: ASSISTANT EXAMINER:

Whisenant, Ethan Tung, Joyce

LEGAL REPRESENTATIVE: Kruse, Norman J., Quine, Jonathan AlanThe Law Office

of

Jonathan Alan Quine

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

Drawing Figure(s); 8 Drawing Page (s) NUMBER OF DRAWINGS:

LINE COUNT:

3923

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 4 OF 40 USPATFULL

MDKI, a novel receptor tyrosine kinase ΤI

The present invention relates to MDK1 polypeptides, nucleic acids AΒ encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing.

Methods for treatment, diagnosis, and screening are provided for diseases or conditions characterized by an abnormality in a signal transduction disorder. The signal transduction pathway involves an interaction between a MDK1 receptor tyrosine kinase and a receptor for the kinase. The MDK1 receptor tyrosine kinase may be truncated and lack a kinase domain and may be selected from the group consisting of MDK1.T1, MDK1.T2, MDK1..DELTA.1 and MDK1..DELTA.2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

2001:173726 USPATFULL ACCESSION NUMBER:

MDKI, a novel receptor tyrosine kinase TITLE:

Ciossek, Thomas, Munich, Germany, Federal Republic of INVENTOR (S):

Ullrich, Axel, Portola Valley, CA, United States Millauer, Birgit, Belmont, CA, United States

Max-Flanck-Gesellschaft Zuer Forderung Der, Munich, PATENT ASSIGNEE(S):

Germany, Federal Republic of (non-U.S. corporation)

DATE NUMBER KIND US 6300482 B1 20011009 US 1995-368776 19950103 (8) PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: Utility GRANTED FILE SEGMENT: Ungar, Susan PRIMARY EXAMINER: LEGAL REPRESENTATIVE: Foley & Lardner

NUMBER OF CLAIMS: 14 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 40 USPATFULL

Method of increasing production of disulfide bonded recombinant ΤI proteins

by saccharomyces cerevisiae

Disclosed is a process for increasing the yield of disulfide bonded AB recombinant proteins produced by yeast, especially recombinant secreted proteins The enzyme protein disulfide isomerase (PDI) catalyzes the formation of disulfide bonds in secretory and cell-surface proteins. We disclose the construction of recombinant strains of the yeast Saccharomyces cerevisiae which overproduce either human PDI or yeast

PDI

in a regulated fashion. These strains show greatly increased secretion of disulfide bonded proteins of potential therapeutic significance. These strains have the potential to increase the production of various disulfide bonded proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

2001:158037 USPATFULL ACCESSION NUMBER:

TITLE: Method of increasing production of disulfide bonded

recombinant proteins by saccharomyces cerevisiae

Tuite, Michael F., Chartham Hatch, United Kingdom INVENTOR(S):

Freedman, Robert B., Canterbury, United Kingdom hultz, Loren D., Harleysville, D., United States Ellis, Ronald W., Newton, MA, United States

Markus, Henry Z., Wyncote, PA, United States

Montgomery, Donna L., Chalfont, PA, United States Merck & Co., Inc., Rahway, NJ, United States (U.S.

PATENT ASSIGNEE(S): corporation)

University of Kent at Canterbury, Kent, United Kingdom

(non-U.S. corporation)

NUMBER KIND DATE ______

US 6291205 B1 20010918 US 1992-901713 19920612 PATENT INFORMATION: 19920612 (7) APPLICATION INFO.:

DOCUMENT TYPE: Utility GRANTED FILE SEGMENT:

Schwartzman, Robert A. PRIMARY EXAMINER:

LEGAL REPRESENTATIVE: Hand, J. Mark, Tribble, Jack L.

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s) LINE COUNT: 1927

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 6 OF 40 USPATFULL

Evolution of whole cells and organisms by recursive sequence ΤI

recombination

The invention provides methods employing iterative cycles of AΒ recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and

capacity for expression and/or secretion of proteins and secondary

metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:152770 USPATFULL

TITLE: Evolution of whole cells and organisms by recursive

sequence recombination

delCardayre, Stephen, Belmont, CA, United States INVENTOR(S):

Tobin, Matthew, San Jose, CA, United States

Stemmer, Willem P. C., Los Gatos, CA, United States

Ness, Jon E., Sunnyvale, CA, United States Minshull, Jeremy, Menlo Park, CA, United States Patten, Phillip, Menlo Park, CA, United States Subramanian, Venkiteswaran, San Diego, CA, United

States

Castle, Linda, Mountain View, CA, United States Krebber, Claus M., Mountain View, CA, United States Bass, Steven H., Hillsborough, CA, United States Maxygen, Inc., Redwood City, CA, United States (U.S.

PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE

US 6287862 B1 20010911 US 2000-626410 20000726 (9) Division of Ser. No. US 1998-116188, filed on 15 Jul PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.:

1998 Continuation-in-part of Ser. No. WO 1998-US852,

filed on 16 Jan 1998

NUMBER DATE _____

PRIORITY INFORMATION: US 1997-35054 19970107 (60)

DOCUMENT TYPE: Utility GRANTED FILE SEGMENT:

PRIMARY EXAMINER:

Whisenant, Ethan Kruse, Norman J., Quine, Jonathan AlanThe Law Offices LEGAL REPRESENTATIVE:

of Jonathan Alan Quine

48 NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 35 Drawing Figure(s); 35 Drawing Page(s)

LINE COUNT: 5146

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 7 OF 40 USPATFULL TI Glaucoma compositions

Glaucoma compositions comprising the GLC1A gene are disclosed. AB

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:125799 USPATFULL Glaucoma compositions TITLE:

Stone, Edwin M., Iowa City, IA, United States INVENTOR(S):

Sheffield, Val C., Coralville, IA, United States Alward, Wallace L. M., Iowa City, IA, United States

The University of Iowa Research Foundation, Iowa City, PATENT ASSIGNEE(S):

IA, United States (U.S. corporation)

NUMBER KIND DATE _____ US 6271026 B1 20010807 US 1997-822999 19970321 (8) PATENT INFORMATION: APPLICATION INFO.:

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

Martin, Jill D. PRIMARY EXAMINER:

LEGAL REPRESENTATIVE: Foley, Hoag & Eliot LLP, Arnold, Beth E., Varma, Anita

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 10 Drawing Figure(s); 6 Drawing Page(s)

LINE COUNT: 3481

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 8 OF 40 USPATFULL

TΙ Evolution of whole cells and organisms by recursive sequence

recombination

The invention provides methods employing iterative cycles of AB recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:97699 USPATFULL

Evolution of whole cells and organisms by recursive TITLE:

sequence recombination

INVENTOR(S): Tobin, Matthew, San Jose, CA, United States

Stemmer, William P. C., Los Gatos, CA, United States

Ness, Jon E., Sunnyvale, CA, United States

Minshull, Jeremy, Menlo Park, CA, United States

Maxygen, Inc., Redwood City, CA, United States (U.S. PATENT ASSIGNEE(S):

corporation)

NUMBER KIND DATE ______ PATENT INFORMATION: US 6251674 B1 20010626 US 2000-499505 20000207 (9) APPLICATION INFO.: RELATED APPLN. INFO.: Division of Ser. No. US 116188

NUMBER DATE

PRIORITY INFORMATION: US 1997-35054 19970107 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Whisenant, Ethan

LEGAL REPRESENTATIVE: Kruse, Norman J., Quine, Jonathan AlanThe Law Offices

of Jonathan Alan Quine

NUMBER OF CLAIMS: 5 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 35 Drawing Figure(s); 35 Drawing Page(s)

LINE COUNT: 5013

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 40 USPATFULL

Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases
Genes encoding Class II EPSPS enzymes are disclosed. The genes are
useful in producing transformed bacteria and plants which are tolerant
to glyphosate herbicide. Class II EPSPS genes share little homology

with

known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:93642 USPATFULL

TITLE: Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate

synthases

INVENTOR(S): Barry, Gerard Francis, St. Louis, MO, United States

Kishore, Ganesh Murthy, Chesterfield, MO, United

States

Padgette, Stephen Rogers, Grover, MO, United States Stallings, William Carlton, Glencoe, MO, United States

PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S.

corporation)

PATENT INFORMATION: US 6248876 B1 20010619 APPLICATION INFO.: US 1998-137440 19980820 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-833485, filed on 7

Apr

1997, now patented, Pat. No. US 5804425 Continuation

of

Ser. No. US 1994-306063, filed on 13 Sep 1994, now patented, Pat. No. US 5633435 Continuation-in-part of Ser. No. US 1991-749611, filed on 28 Aug 1991, now abandoned Continuation-in-part of Ser. No. US

abandoned Continuation-in-part of Ser. No. US 1990-576537, filed on 31 Aug 1990, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Slobodyansky, Elizabeth

LEGAL REPRESENTATIVE: Bonner, Esq., Grace L., Simon, HowreyArnold & White

LLP

NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 70 Drawing Figure(s); 70 Drawing Page(s)

LINE COUNT: 3117

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 40 USPATFULL

TI Nucleic acids that control endosperm development in plants

AB The invention prodes methods of controlling endomerm development in

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:67875 USPATFULL

TITLE: Nucleic acids that control endosperm development in

plants

INVENTOR(S): Fischer, Robert L., El Cerrito, CA, United States

Ohad, Nir, Jerusalem, Israel

Kiyosue, Tomohiro, Okazaki, Japan

Yadegari, Ramin, San Jose, CA, United States Margossian, Linda, El Cerrito, CA, United States

Harada, John, Davis, CA, United States

Goldberg, Robert B., Topanga, CA, United States

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,

CA, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6229064 B1 20010508 APPLICATION INFO.: US 1998-177249 19981022 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-71838, filed

on 1 May 1998

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Hutzell, Paula
ASSISTANT EXAMINER: Mehta, Ashwin D.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

LEGAL REPRESENTATIVE: Town:
NUMBER OF CLAIMS: 22

EXEMPLARY CLAIM: 1,12

NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)

LINE COUNT: 1399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:39:10 ON 28 DEC 2001)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, JAPIO, EMBASE' ENTERED AT 18:39:35 ON 28 DEC 2001

L1 0 S CODON REPLACMENT

L2 107597 S CODON

L3 7806 S L2 AND REPLACEMENT

L4 101 S L3 AND ENCODING PROTEIN

L5 40 S L4 AND FREQUENCY L6 0 S L5 AND LESS COMMON

=> d 15 ti abs ibib 30-40

L5 ANSWER 30 OF 40 USPATFULL

TI Polynucleotides encoding improved humanized immunoglobulins

AB Novel methods for producing, and compositions of, humanized

immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are

immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The

heavv

and light chains may each be designed by using any one or all of

various

position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

97:112587 USPATFULL ACCESSION NUMBER: TITLE:

Polynucleotides encoding improved humanized

immunoglobulins

Queen, Cary L., Los Altos, CA, United States INVENTOR(S):

Schneider, William P., Mountain View, CA, United

States

Selick, Harold E., Belmont, CA, United States

Protein Design Labs, Inc., Mountain View, CA, United PATENT ASSIGNEE(S):

States (U.S. corporation)

DATE NUMBER KIND _____ US 5693761 19971202 PATENT INFORMATION: APPLICATION INFO.: US 1995-474040 19950607

Division of Ser. No. US 1990-634278, filed on 19 Dec RELATED APPLN. INFO.:

1990, now patented, Pat. No. US 5530101, issued on 25

Jun 1996 which is a continuation of Ser. No. US

1990-590274, filed on 28 Sep 1990, now abandoned And a continuation of Ser. No. US 1989-310252, filed on 13 Feb 1989, now abandoned which is a continuation of

Ser.

No. US 1988-290975, filed on 28 Dec 1988, now

abandoned

Utility DOCUMENT TYPE: Granted FILE SEGMENT: PRIMARY EXAMINER: Feisee, Lila Reeves, Julie E. ASSISTANT EXAMINER:

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: 37 EXEMPLARY CLAIM:

80 Drawing Figure(s); 55 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 4810

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 31 OF 40 USPATFULL Ь5

Fusion proteins comprising circularly permuted ligands TI

AB The present invention provides for circularly permuted ligands which possess specificity and binding affinity comparable to or greater than the specificity and binding affinity of the original (unpermuted) ligand. The invention further provides for novel fusion proteins comprising a circularly permuted ligand fused to one or more proteins

of

interest.

CAS INDEXING IS AVAILABLE FOR THIS PATENT. 97:47503 USPATFULL ACCESSION NUMBER:

TITLE: Fusion proteins comprising circularly permuted ligands

Pastan, Ira H., Potomac, MD, United States INVENTOR(S): Kreitman, Robert J., Potomac, MD, United States

Puri, Raj K., North Potomac, MD, United States

The United States of America as represented by the PATENT ASSIGNEE(S):

Department of Health and Human Services, Washington,

DC, United States (U.S. government)

NUMBER KIND DATE -----

US 5635599 19970603 PATENT INFORMATION: 19940408 (8) US 1994-225224 APPLICATION INFO.:

DOCUMENT TYPE: Utility Granted FILE SEGMENT:

Walsh, Stephen G. PRIMARY EXAMINER: Kemmerer, Elizabeth C. ASSISTANT EXAMINER:

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew

NUMBER OF CLAIMS: 17 EXEMPLARY CLAIM:

10 Drawing Figure(s); 4 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 1966

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 32 OF 40 USPATFULL

Method of detecting ligand interactions TΙ

Provided by the present invention are novel methods of detecting ligand AB interactions, as well as regents useful in the method, including DNA

and

host cells; and more specifically relates to novel methods for the detection of protein/protein interactions and their application in epitope mapping and the study of ligand/receptor interactions. Also provided are vaccines and kits comprising the expression products and host cells of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

97:47098 USPATFULL ACCESSION NUMBER:

Method of detecting ligand interactions TITLE: McCoy, John M., Reading, MA, United States INVENTOR(S): Lu, Zhijian, Arlington, MA, United States

Genetics Institute, Inc., Cambridge, MA, United States PATENT ASSIGNEE(S):

(U.S. corporation)

KIND DATE NUMBER ______

19970603 PATENT INFORMATION: US 5635182 19940616 (8) US 1994-260582 APPLICATION INFO.:

20101214 DISCLAIMER DATE: DOCUMENT TYPE: Utility Granted FILE SEGMENT:

PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Bugalsky, Gabriele E.

LEGAL REPRESENTATIVE: Meinert, M. C.

28 NUMBER OF CLAIMS: EXEMPLARY CLAIM:

7 Drawing Figure(s); 7 Drawing Page(s) NUMBER OF DRAWINGS:

1935 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 33 OF 40 USPATFULL L5

Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases TΙ Genes encoding Class II EPSPS enzymes are disclosed. The genes are AB useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology

with

known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.

CAS INDEXING IS AVAIL FOR THIS PATENT.
ACCESSION NUMBER: 97:45193 USPATFULL

TITLE: Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate

synthases

INVENTOR(S): Barry, Gerard F., St. Louis, MO, United States

Kishore, Ganesh M., Chesterfield, MO, United States Padgette, Stephen R., Grover, MO, United States Stallings, William C., Glencoe, MO, United States

PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S.

corporation)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-749611, filed

on 28 Aug 1991, now abandoned which is a

continuation-in-part of Ser. No. US 1990-576537, filed

on 31 Aug 1990, now abandoned

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Chereskin, Che S.

LEGAL REPRESENTATIVE: Hoerner, Jr., Dennis R.

NUMBER OF CLAIMS: 87 EXEMPLARY CLAIM: 4

NUMBER OF DRAWINGS: 70 Drawing Figure(s); 70 Drawing Page(s)

LINE COUNT: 3863

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 40 USPATFULL

Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases

Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant

to glyphosate herbicide. Class II EPSPS genes share little homology

with

known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.

CAS INDEXING IS AVAILABLE FOR THIS PATENT. ACCESSION NUMBER: 97:38404 USPATFULL

TITLE: Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate

synthases

INVENTOR(S): Barry, Gerard F., St. Louis, MO, United States

Kishore, Ganesh M., Chesterfield, MO, United States Padgette, Stephen R., Grover, MO, United States Stallings, William C., Glencoe, MO, United States

PATENT ASSIGNEE(S): Monsanto Company, St. Louis, MO, United States (U.S.

corporation)

PATENT INFORMATION: US 5627061 19970506 APPLICATION INFO.: US 1995-476008 19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-306063, filed on 13

Sep 1994 which is a continuation-in-part of Ser. No. US

1991-749611, filed on 28 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-576537,

filed on 31 Aug 1990, now abandoned

DOCUMENT TYPE: Utility ranted FILE SEGMENT:

PRIMARY EXAMINER: hereskin, Che S.

Hoerner, Jr., Dennis R. LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 70 Drawing Figure(s); 70 Drawing Page(s)

3576 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 35 OF 40 USPATFULL

Virulence-encoding DNA sequences of Strepococcus suis and related ΤI

products and methods

The invention provides DNA sequences which code for polypeptides which AB are characteristic for the virulence of the pathogenic bacterium Streptococcus suis and parts thereof, and polypeptides and antibodies

derived therefrom. The sequences code for a polypeptide of

90,000-120,000 daltons or a polypeptide of higher molecular weight containing such a polypeptide, and for a polypeptide of 135,000-136,000 daltons (muramidase released protein), or parts thereof. The sequences themselves, and also the polypeptides and antibodies derived therefrom, are used for diagnosis of and protection against infection by S. suis

in

mammals, including man.

CAS INDEXING IS AVAILABLE FOR THIS PATENT. ACCESSION NUMBER: 97:20384 USPATFULL

Virulence-encoding DNA sequences of Strepococcus suis TITLE:

and related products and methods

Smith, Hilda E., Cz Lelystad, Netherlands INVENTOR(S):

Vecht, Uri, As Ermelo, Netherlands

Centraal Diergeneeskundig Instituut, PH Lelystad, PATENT ASSIGNEE(S):

Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5610011 WO 9216630		19970311 19920110	
APPLICATION INFO.:	US 1993-119125 WO 1992-NL54		19930920 19920319	(8)
	WO 1992-NL34		19930920	PCT 371

date 19930920 PCT 102(e) date

NUMBER DATE PRIORITY INFORMATION: NL 1991-510 19910321

DOCUMENT TYPE: Utility Granted FILE SEGMENT:

Campell, Bruce R. PRIMARY EXAMINER: LEGAL REPRESENTATIVE: Handal & Morofsky

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Figure(s); 13 Drawing Page(s)

LINE COUNT: 2515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 36 OF 40 USPATFULL L5

ΤI Humanized immunoglobulins

Novel methods for producing, and compositions of humanized ΑB immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin

framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amin acids which are immediately adjusted to a CDR in the donor immuno obulin or those within about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

96:116100 USPATFULL ACCESSION NUMBER:

TITLE:

Humanized immunoglobulins

INVENTOR(S):

Queen, Cary L., Los Altos, CA, United States

Selick, Harold E., Belmont, CA, United States

PATENT ASSIGNEE(S):

Protein Design Labs, Inc., Mountain View, CA, United

States (U.S. corporation)

NUMBER KIND DATE -----

PATENT INFORMATION:

US 5585089 19961217 US 1995-477728 19950607

APPLICATION INFO.: RELATED APPLN. INFO.:

Continuation of Ser. No. US 1990-634278, filed on 19 Dec 1990, now patented, Pat. No. US 5530101 which is a continuation-in-part of Ser. No. US 1990-590274, filed

on 28 Sep 1990, now abandoned And Ser. No. US

1989-310252, filed on 13 Feb 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-290975,

filed on 28 Dec 1988, now abandoned

DOCUMENT TYPE: FILE SEGMENT:

AΒ

Utility Granted Feisee, Lila

PRIMARY EXAMINER:

Townsend and Townsend and Crew LLP

LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM:

11

NUMBER OF DRAWINGS:

80 Drawing Figure(s); 55 Drawing Page(s)

LINE COUNT: 4605

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 37 OF 40 USPATFULL T.5

Humanized immunoglobulins ΤI

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoqlobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

CAS INDEXING IS AVAILABLE FOR THIS PATENT. ACCESSION NUMBER: 96:55856 USPATFULL

Humanized immunoglobulins TITLE:

Queen, Cary L., Los Altos, CA, United States INVENTOR(S): Selick, Harold E., Belmont, CA, United States PATENT ASSIGNEE(S): Protein Design Labs, Inc., Mountain View, CA, United

States (U.S. corporation)

PATENT INFORMATION: US 5530101 19960625
APPLICATION INFO.: US 1990-634278 19901219

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-590274, filed

on 28 Sep 1990, now abandoned And a

continuation-in-part of Ser. No. US 1989-310252, filed

(7)

on 13 Feb 1989, now abandoned which is a

continuation-in-part of Ser. No. US 1988-290975, filed

on 28 Dec 1988, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew

NUMBER OF CLAIMS: 13 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 80 Drawing Figure(s); 55 Drawing Page(s)

LINE COUNT: 4526

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 40 USPATFULL

TI Process for the site-directed integration of DNA into the genome of plants

AB The present invention provides a method for site-directed integration of

 ${\tt DNA-sequences}$ into the genome of plants via homologous recombination, by

transforming said plants using the DNA-transfer system of Agrobacterium,

in which the transforming DNA comprises in its most simple form a region

homologous to the target locus, as well as a region which is different from the target locus either next to one or between two T-DNA borders. Special constructs are provided, which in its most complete form have the following general structure, ##STR1## in which box 1 and 7 represent

T-DNA borders, boxes 2 and 6 comprise functional expression cassettes containing negative selection genes, box 3 provides a region of homology

with the target locus promoting recombination, box 4 represents a DNA sequence containing a mutation with respect to the target locus, box 5 represents a functional expression cassette containing a positive selection gene, and box E comprises a DNA sequence which is homologous to a region adjacent of the target locus, or in the vicinity of the target locus, which promotes homologous recombination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:24854 USPATFULL

TITLE: Process for the site-directed integration of DNA into

the genome of plants

INVENTOR(S): Offringa, Remko, Leiden, Netherlands

De Groot, Marcellus J. A., Utrecht, Netherlands Hooykaas, Paul J. J., Oegstgeest, Netherlands Van Den Elzen, Petrus J. M., Voorhout, Netherlands

PATENT ASSIGNEE(S): Mogen International, n.v./Rijksuniversiteit te Leiden,

Leiden, Netherlands (non-U.S. corporation)

 RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-659288, filed on 21

May 1991, now abandoned

NUMBER DATE

PRIORITY INFORMATION: NL 1989-1931 19890726

DOCUMENT TYPE:

Utility Granted

FILE SEGMENT: PRIMARY EXAMINER:

Fox, David T.

LEGAL REPRESENTATIVE: Morrison & Foerster

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

19 1

NUMBER OF DRAWINGS:

15 Drawing Figure(s); 14 Drawing Page(s)

LINE COUNT:

1812

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 39 OF 40 USPATFULL

DNA encoding 85kd polypeptide useful in diagnosis of Mycoplasma ΤI

infections in animals

A class of polypeptides useful in an in vitro diagnosis of Mycoplasma AB

infection in animals is disclosed. These polypeptides are also capable of inducing an immune response in swine which were previously not exposed to Mycoplasma. Recombinant DNA methods for the production of these polypeptides and certain phage vectors and DNA sequences useful

in

these methods are also disclosed. Methods of vaccinating animals utilizing a vaccination composition which includes these polypeptides

is

also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

95:92697 USPATFULL

TITLE:

DNA encoding 85kd polypeptide useful in diagnosis of

Mycoplasma infections in animals

INVENTOR (S):

Kuner, Jerry, Longmont, CO, United States Ko, Christine, Boulder, CO, United States

PATENT ASSIGNEE(S):

Synergen, Inc., Boulder, CO, United States (U.S.

corporation)

NUMBER DATE KIND

PATENT INFORMATION:

US 5459048

19951017